WHO recommendations for influenza virus vaccine composition for the 2019–2020 northern hemisphere season
On 18–20 February 2019, the World Health Organization (WHO) agreed on the recommended composition of the quadrivalent influenza vaccine for the northern hemisphere 2019–2020 influenza season: an A/Brisbane/02/2018 (H1N1)pdm09-like virus, an A(H3N2) virus component to be announced on 21 March 2019, a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage) and a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage). The WHO recommendations are based on the viruses currently circulating globally. The WHO recommendation represents a change in the (H1N1)pdm09 component. Compared to the current trivalent and quadrivalent vaccines for the 2018–2019 season in the northern hemisphere influenza season, the B virus components are unchanged from 2018–2019. Due to the genetic and antigenic diversity of recently circulating A(H3N2) viruses, the recommendation of the A(H3N2) virus component has been postponed to allow more time for the selection of the appropriate virus.
On 18–20 February 2019 in Beijing, China, the World Health Organization (WHO) agreed on the recommended composition of the quadrivalent influenza vaccine for the northern hemisphere 2019–2020 influenza season: an A/Brisbane/02/2018 (H1N1)pdm09-like virus, a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage), a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage) and an A(H3N2) virus component to be announced on 21 March 2019. The recommendation for the A(H3N2) component was postponed in light of recent changes in the proportions of genetically and antigenically diverse A(H3N2) viruses to allow more time for the selection of the appropriate virus strain. It is recommended that the influenza B virus component of trivalent vaccines for use in the 2019–2020 northern hemisphere influenza season be a B/Colorado/06/2017-like virus of B/Victoria/2/87-lineage.
The WHO recommendations are based on the viruses currently circulating globally. These viruses are collected through intensive surveillance efforts, where European laboratories and ECDC play a major role.
WHO recommended a change in the (H1N1)pdm09 component compared to the current trivalent and quadrivalent vaccines for the northern hemisphere 2018–2019 influenza season. The majority of circulating A(H1N1)pdm09 viruses have haemagglutinin (HA) gene sequences that belong to the genetically diverse phylogenetic subclade 6B.1A. In Europe and worldwide, predominant viruses also carry amino acid substitution S183P in HA1. Although almost all currently circulating A(H1N1)pdm09 viruses are antigenically similar to the 2018–2019 vaccine virus A/Michigan/45/2015 in haemagglutination inhibition (HI) assays, serological studies showed that a virus component representing this newly emergent subgroup would be more appropriate. The A(H1N1)pdm09 virus component was therefore changed from A/Michigan/45/2015 to A/Brisbane/02/2018.
There is considerable genetic and antigenic diversity of recently circulating A(H3N2) viruses. The majority of circulating A(H3N2) viruses in Europe belong to the phylogenetic subclade 3C.2a1b. However, the number of clade 3C.3a viruses has increased substantially since November 2018 in several geographic regions in Europe and worldwide. The 3C.2a and 3C.3a viruses are antigenically distinct. A low proportion of A(H3N2) viruses was inhibited well by antisera raised against the 2018–2019 egg-propagated vaccine virus A/Singapore/INFIMH-16-0019/2016, while none of the 3C.3a viruses were recognised by the 2018–2019 vaccine virus. The recommendation for the A(H3N2) vaccine component will be announced by WHO in 21 March 2019.
In Europe and globally, both B virus lineages co-circulate in very low numbers. All circulating B/Yamagata/16/88 lineage viruses are well inhibited by antisera raised against B/Phuket/3073/2013. The same component was retained for the quadrivalent 2019–2020 vaccine.
WHO recommended the inclusion of the B/Victoria lineage in the trivalent vaccine for the northern hemisphere 2019–2020 influenza season. All circulating B/Victoria viruses belong to clade 1A, but are genetically and antigenically diverse, with the majority belonging to either the subgroup that carries two amino acid deletions (Δ2) or the one that carries three amino acid deletions (Δ3) in HA. The recommended 2018–2019 vaccine virus B/Colorado/06/2017 that belongs to the Δ2 subgroup was retained for the trivalent and quadrivalent 2019–2020 vaccines.
Further antigenic and genetic characteristics of recent seasonal influenza viruses are described in the full report of the recommendation.
See more news on influenza and vaccines
More on the topic
Flu News Europe: Weekly influenza updates
Weekly reports on influenza activity in Europe throughout the flu season are available as Flu News Europe reports and weekly infographic.Read more
WHO recommendations for influenza virus vaccine composition for the 2018-2019 Northern hemisphere season
26 Feb 2018 - On 19-21 February 2018 the World Health Organization (WHO) agreed on the recommended composition of the trivalent influenza vaccine for the northern hemisphere 2018-2019 influenza season.
Influenza vaccination coverage rates insufficient across EU Member States
18 Dec 2018 - None of the European Union (EU) Member States could demonstrate that they reach the EU target of 75% influenza vaccination coverage for vulnerable groups, according to a new report from the European Centre for Disease Prevention and Control (ECDC).
Interim 2017/18 influenza seasonal vaccine effectiveness: Combined results from five European studiesRead more
ECDC to implement key council recommendations on vaccination
7 Dec 2018 - In a Council Recommendation adopted by EU health ministers today, ECDC has been called on to implement a number of key actions in the fight against vaccine-preventable diseases.
Influenza virus characterisation, Summary Europe, December 2018
21 Jan 2019 - This is the third report for the 2018–19 influenza season. As of week 1/2019, 18 049 influenza detections across the WHO European Region had been reported. Detections were made up of 97.7% type A viruses, with A(H1N1)pdm09 prevailing over A(H3N2), and 2.3% type B viruses, with 16 (64%) of 25 ascribed to a lineage being B/Yamagata.